CSTLCastle Biosciences, Inc.

NAS · US · Healthcare · Diagnostics & Research · castlebiosciences.com

34.20USD+5.82%Mkt Cap: 1.04B $P/E: —3d ago

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The compan…

Industry Peers

Diagnostics & Research

Screen all

TMO

Thermo Fisher Scientific Inc.

Agilent Technologies, Inc.

$44.91BUSDP/E 31.9

IDXX

IDEXX Laboratories, Inc.

Mettler-Toledo International, Inc.

$27.96BUSDP/E 31.5

Labcorp Holdings Inc.

$27.28BUSDP/E 27.8

DGX

Quest Diagnostics Incorporated

$26.97BUSDP/E 26.0

Guardant Health, Inc.

$22.91BUSD

MEDP

Medpace Holdings, Inc.

$17.33BUSDP/E 36.4

ERF

Eurofins Scientific SE

$13.65BUSDP/E 25.3

CRL

Charles River Laboratories International, Inc.

$14.09BUSD

RVTY

Revvity Inc. Common Stock

$13.92BUSDP/E 59.7

ICLR

ICON Public Limited Company

Twist Bioscience Corp.

$9.13BUSD

Key Statistics

Company

Market Cap1.04B $

Enterprise Value775.84M $

Revenue (TTM)357.28M $

Gross Profit273.20M $

Net Income (TTM)-24.16M $

Revenue/Share12.04 USD

Last Price34.20 USD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees1.0K

CountryUS

SectorHealthcare

IndustryDiagnostics & Research

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-33.30

PEG—

EV/EBITDA-46.98

EV/Revenue2.17

P/S2.82

P/B2.14

EPS (TTM)-0.65

EPS (Forward)-0.99

52W Range

17.7262% of range44.28

52W High44.28 USD

52W Low17.72 USD

Profitability

Gross Margin79.37%

Oper. Margin-2.96%

EBITDA Margin-4.62%

Profit Margin-7.02%

ROE-5.13%

ROA-4.18%

Growth

Revenue Growth20.10%

Earnings Growth—

Cash Flow & Leverage

Operating CF64.35M $

CapEx (TTM)36.02M $

FCF Margin-2.03%

FCF Yield-0.69%

Net Debt-230.15M $

Net Debt/EBITDA13.94

Balance Sheet

Debt/Equity0.08

Current Ratio6.04

Quick Ratio5.60

Book Value/Sh15.41 USD

Cash/Share8.734 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.0000 USD

Div. Yield—

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating1.0 (Strong Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)44.00 USD

Upside (mean)+28.7%

Target Range35.00 USD – 57.00 USD

$35.00+28.7% to mean$57.00

# Analysts9

Ownership

Shares Out.30.55M

Float27.05M

Insiders2.48%

Institutions90.85%

Short Interest

Short Ratio4.1d

Short % Float5.24%

Short % Out.5.11%

Shares Short1.56M

Short (prev mo.)1.49M

Technical

SMA 5025.57 (+33.8%)

SMA 20029.39 (+16.4%)

Beta0.97

S&P 52W Chg18.16%

Avg Vol (30d)422.74K

Avg Vol (10d)361.56K

Technical Indicators

RSI (14)73.2

MACD2.0843

MACD Signal1.9558

MACD Hist.+0.1285

BB Upper35.61 USD

BB Middle29.24 USD

BB Lower22.88 USD

BB Width43.55%

ATR (14)1.717 USD

Vol Ratio (20d)1.17x